DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY

Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Assudani D, Kumke T, Ink B, Mcinnes I (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 127-128

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

Event location: Madrid

DOI: 10.1136/annrheumdis-2019-eular.4883

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Harvard University

United States (USA) (US) University of Glasgow

United Kingdom (GB) UCB Pharma Ltd

United Kingdom (GB) University of Manchester

United Kingdom (GB) NYU Langone Medical Center

United States (USA) (US) University of Rochester (UR)

United States (USA) (US) University of California, San Diego

United States (USA) (US)

How to cite

APA:

Ritchlin, C.T., Kavanaugh, A., Merola, J.F., Schett, G., Scher, J.U., Warren, R.B.,... Mcinnes, I. (2019). DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. In ANNALS OF THE RHEUMATIC DISEASES (pp. 127-128). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:

Ritchlin, Christopher T., et al. "DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 127-128.

BibTeX: Download